SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:0250 7005 OR L773:1791 7530 ;srt2:(2015-2019)"

Sökning: L773:0250 7005 OR L773:1791 7530 > (2015-2019)

Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
31.
  • Leandersson, Pia, et al. (författare)
  • Ovarian Cancer Surgery : a Population-based Registry Study
  • 2017
  • Ingår i: Anticancer Research. - INT INST ANTICANCER RESEARCH. - 0250-7005 .- 1791-7530. ; 37:4, s. 1837-1845
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Background/Aim: To evaluate ovarian cancer surgery in tertiary centers (TC) and regional hospitals (RH). Patients and Methods: Data from the GynOp registry on patients undergoing surgery for ovarian cancer or borderline tumor from 2013 to 2015 were analyzed. Results: Four TC and 21 RH reported 1,108 cases of surgery with curative intent, 770 cases (69.5%) in TC and 338 cases (30.5%) in RH. Out of 458 patients with International Federation of Gynecology and Obstetrics (FIGO) stage IIIC-IV disease 396 (86.5%) had surgery in TC. We found differences in selection for primary debulking surgery (PDS) (45% to 93%, p&lt;0.001) and PDS achieving no residual tumor (36% to 70%, p&lt;0.001) between the four TC. Major complications, re-admissions and re-operation rates did not differ between TC and RH. Conclusion: Tertiary centers perform more extensive surgery compared to regional hospitals without increased frequency of major complications. Tertiary centers display significant differences among patient selection for PDS, as well as achieving no residual tumor.</p>
  •  
32.
  • Lewin, Nongnit, et al. (författare)
  • The Influence of Adjuvant Radiotherapy and Single Nucleotide Polymorphisms on Circulating Immune Response Cell Numbers and Phenotypes of Patients With Breast Cancer
  • 2019
  • Ingår i: Anticancer Research. - INT INST ANTICANCER RESEARCH. - 0250-7005 .- 1791-7530. ; 39:9, s. 4957-4963
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Background/Aim: Adjuvant radiotherapy (RT) damages multiple layers of skin, muscle, blood vessels and blood cells that are included within the RT area. Indirect, bystander systemic effects could also develop in cells not directly hit by radiation. Materials and Methods: Ninety-three female patients recovering from breast cancer surgery and 82 female healthy blood donors were analyzed. For identification of systemic adaptive and innate immune response, rapid and low-cost blood-based biomarkers were assayed. Results: Post-operated breast cancer patients had a decreased number of circulating adaptive immune response cells but increased number of circulating immunosuppressive myeloid subpopulations. RT decreased the number of T-cells and platelets without influencing the number of immunosuppressive myeloid subpopulations. Alterations in the number and phenotypes of T-cell subpopulations were associated with SNPs. Conclusion: The combination of RT and immunotherapy might provide optimal treatment for cancer patients.</p>
  •  
33.
  • Lewin, Nongnit, et al. (författare)
  • The Influence of Single Nucleotide Polymorphisms and Adjuvant Radiotherapy on Systemic Inflammatory Proteins, Chemokines and Cytokines of Patients With Breast Cancer
  • 2019
  • Ingår i: Anticancer Research. - INT INST ANTICANCER RESEARCH. - 0250-7005 .- 1791-7530. ; 39:3, s. 1287-1292
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Independently of tumour and treatment modulation, the host immune response status plays an important role in the clinical outcome of patients with cancer. The influence of single nucleotide polymorphisms (SNPs) and adjuvant radiotherapy (RT) on the systemic immune response status of patients with breast cancer was investigated. Materials and Methods: Eighty-six female patients recovering from breast cancer surgery were investigated. As a control cohort, 82 healthy female blood donors were used. Blood-based SNPs, plasma C-reactive protein (CRP), cytokines and chemokines were analyzed for this purpose. Results: Independently of tumour stage and hormone receptor status, dysregulation of plasma CRP, chemokine (C-C motif) ligand 4 (CCL4) and interleukin 2 (IL2), but not CCL5, CCL2, platelet-derived growth factor, IL6, IL10, IL12, interferon-gamma or tumour necrosis factor alpha were detected in the patients when compared to controls. The extent of alteration in plasma levels of CRP and IL2 patients was significantly associated with SNPs in CRP rs1800947 and IL2 rs6822844, respectively. These SNPs had no influence on the levels of corresponding plasma biomarkers in the healthy controls. Adjuvant RT reduced plasma CRP and CCL5 levels in patients with regards to CRP rs1800947CC, CCL5 rs2107538GG and CCL5 rs2280789AA sequences. Conclusion: Dysregulation of immune responses, as indicated by plasma levels of CRP, CCL4 and IL2 were found in patients with breast cancer despite the removal of the tumour mass. The benefit of adjuvant RT, as indicated by reduced plasma amounts of inflammatory protein CRP and chemokine CCL5 were based on the SNPs of the patients. Analyses of blood-based SNPs, plasma CRP, IL2 and CCL5 are low cost, rapid and can be carried out using general laboratory facilities while requiring only a peripheral blood sample. The possibility of using these blood-based biomarkers as an indicator of patient immune status for selection of individual patient treatment warrants further investigation.</p>
  •  
34.
  • Lindblom, Emely Kjellsson, et al. (författare)
  • Radiation-induced Vascular Damage and the Impact on the Treatment Outcome of Stereotactic Body Radiotherapy
  • 2019
  • Ingår i: Anticancer Research. - INT INST ANTICANCER RESEARCH. - 0250-7005 .- 1791-7530. ; 39:6, s. 2721-2727
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Background/Aim: The aim of this study was to investigate radiation-induced tumour vascular damage and its impact thereof on the outcome of stereotactic body radiotherapy (SBRT). Materials and Methods: Vessel densities in animal tumours before and after a single dose of 20 Gy were quantified and used as input for simulations of three-dimensional tumours with heterogeneous oxygenation. SBRT treatments of the modelled tumours in 1-8 fractions were simulated. The impact of vessel collapse on the outcome of SBRT was investigated by calculating tumour control probability (TCP) and the dose required to obtain a TCP of 50% (D-50). Results: A radiation-induced increase of acute hypoxia in tumours during SBRT treatment could be simulated based on the experimental data. The D-50 values for these tumours were higher than for the simulated tumours without vessel collapse. Conclusion: The vascular changes after high doses of radiation could compromise the outcome of SBRT by increasing tumour hypoxia.</p>
  •  
35.
  • Lundberg, Ida, et al. (författare)
  • MicroRNA expression in <em>KRAS</em>- and <em>BRAF</em>-mutated colorectal cancers
  • 2018
  • Ingår i: Anticancer Research. - International Institute of Anticancer Research. - 0250-7005 .- 1791-7530. ; 38:2, s. 677-683
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Background/Aim: KRAS and BRAF are two genes commonly mutated in colorectal cancer (CRC). Even though BRAF is a downstream target of KRAS in the MAPK signalling pathway, KRAS- and BRAF-mutated CRCs are found to display several different clinical and histopathological features. We investigated whether a differential expression of microRNAs (miRNAs) could explain the clinicopathological differences seen between KRAS-and BRAF-mutated CRCs.</p><p>Materials and Methods: Using a PCR array, we analyzed the expression of 84 different miRNAs in CRC cell lines wild-type in KRAS and BRAF, or mutated in KRAS or BRAF.</p><p>Results: Ten miRNAs were selected for further analyses in tumor tissue specimens (let-7a, let-7i, miR-10a, miR-10b, miR-31, miR-100, miR-181a, miR-181b, miR-372, and miR-373). BRAF-mutated tumors were found to express significantly higher levels of miR-31 as well as significantly lower levels of miR-373, compared to wild-type tumors.</p><p>Conclusion: Our results suggest that KRAS and BRAF-mutated CRCs may have different miRNA signatures compared to CRC tumors wild-type in KRAS and BRAF. However, no difference in expression levels between KRAS-and BRAF-mutated tumors was evident for the miRNAs analyzed in this study.</p>
  •  
36.
  • Lundin, Erik, 1970-, et al. (författare)
  • Validation of a Clinical Cancer Register at the Head and Neck Oncology Center in Orebro
  • 2019
  • Ingår i: Anticancer Research. - International Institute of Anticancer Research. - 0250-7005 .- 1791-7530. ; 39:1, s. 285-289
  • Tidskriftsartikel (refereegranskat)abstract
    • <p><strong>Background</strong>: This was a validation study of a regional register of oral cancer in Örebro, Sweden. The purpose was to assess the rate of errors in baseline, and treatment, and the completeness and accuracy of data on recurrences.</p><p><strong>Materials and Methods</strong>: A total of 653 cases with squamous cell cancer in the oral cavity were identified from the register. A randomized sample of 73 (11%) was selected, and a set of relevant data was compared to medical records.</p><p><strong>Results</strong>: Data on patient and tumour characteristics showed high accuracy, with 98% correct data and more than 99% of treatment data were correct. Follow-up data had a higher rate of errors, with 23% of recurrences not recorded, 13.6% misclassified, and 9.1% of cases showing errors in timing of the recurrence.</p><p><strong>Conclusion</strong>: data concerning patients, tumour status, and treatment in the Regional Head and Neck Register in Örebro are highly accurate. However, the follow-up data contain a higher rate of errors, that must be taken into consideration when evaluating outcome after treatment.</p>
  •  
37.
  • Marikkannu, Rajeshwari, et al. (författare)
  • Whole-genome Linkage Analysis and Sequence Analysis of Candidate Loci in Familial Breast Cancer
  • 2015
  • Ingår i: Anticancer Research. - 0250-7005 .- 1791-7530. ; 35:6, s. 3155-3165
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Background: Known breast cancer-predisposing genes account for fewer than 25% of all familial breast cancer cases and further studies are required to find the remaining high-and moderate-risk genes. We set-out to couple linkage analysis using microsatellite marker data and sequence analysis of linked regions in 13 non-BRCA1/2 families in order to find novel susceptibility loci and high-penetrant genes. Materials and Methods: Genotyping with 540 fluorescently-labeled microsatellite markers located on the 23 chromosomes at 7.25 cM resolution was used for primary linkage analysis and an additional 40 markers were used for fine-mapping of loci with a logarithm of odds (LOD) or heterogeneity LOD (HLOD) score greater than one. Whole-exome sequencing data of 28 members from all 13 families were used for the bioinformatics sequence analysis on the linked regions of these families. Results: Linkage analysis identified three loci on chromosome 18q as a putative region of interest (overall LOD=1, HLOD=1.2). Sequencing analysis of the three linked regions on 18q and mutation prediction algorithms did reveal three probable damaging variants. Conclusion: Overall, our study identified three weakly linked loci on 18q and three probable damaging variants of interest in the 13 families with breast cancer.</p>
  •  
38.
  • Mondlane, Gracinda, 1987-, et al. (författare)
  • Estimation of Risk of Normal-tissue Toxicity Following Gastric Cancer Radiotherapy with Photon- or Scanned Proton-beams
  • 2018
  • Ingår i: Anticancer Research. - 0250-7005 .- 1791-7530. ; 38:5, s. 2619-2625
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Background/Aim: Gastric cancer (GC) radiotherapy involves irradiation of large tumour volumes located in the proximities of critical structures. The advantageous dose distributions produced by scanned-proton beams could reduce the irradiated volumes of the organs at risk (OARs). However, treatment-induced side-effects may still appear. The aim of this study was to estimate the normal tissue complication probability (NTCP) following proton therapy of GC, compared to photon radiotherapy. Patients and Methods: Eight GC patients, previously treated with volumetric-modulated arc therapy (VMAT), were retrospectively planned with scanned proton beams carried out with the single-field uniform-dose (SFUD) method. A beam-specific planning target volume was used for spot positioning and a clinical target volume (CTV) based robust optimisation was performed considering setup- and range-uncertainties. The dosimetric and NTCP values obtained with the VMAT and SFUD plans were compared. Results: With SFUD, lower or similar dose-volume values were obtained for OARs, compared to VMAT. NTCP values of 0% were determined with the VMAT and SFUD plans for all OARs (p&gt;0.05), except for the left kidney (p&lt;0.05), for which lower toxicity was estimated with SFUD. Conclusion: The NTCP reduction, determined for the left kidney with SFUD, can be of clinical relevance for preserving renal function after radiotherapy of GC.</p>
  •  
39.
  • Månsson, Christopher, Läkarexamen, 1977-, et al. (författare)
  • Percutaneous Irreversible Electroporation as First Line Treatment of Locally Advanced Pancreatic Cancer
  • 2019
  • Ingår i: Anticancer Research. - 0250-7005 .- 1791-7530. ; 39:5, s. 2509-2512
  • Tidskriftsartikel (refereegranskat)abstract
    • <p><strong>Background/Aim:</strong></p><p>Irreversible electroporation (IRE) has recently been used as an experimental ablation treatment following systemic chemotherapy in locally advanced pancreatic cancer (LAPC). The primary aim of this study was to evaluate survival of LAPC patients after IRE prior to chemotherapy. The secondary aim was to examine the complication rates.</p><p><strong>Patients and Methods:</strong></p><p>Twenty-four patients with LAPC were included and treated with percutaneous ultrasound-guided IRE under general anesthesia. Survival data from the National Quality Registry for Pancreatic and Periampullary Cancer for LAPC during the same period were used for comparison.</p><p><strong>Results:</strong></p><p>The median survival after diagnosis was 13.3 months in the IRE group compared to 9.9 months in the registry group (p=0.511). Six patients had a severe complication after IRE treatment.</p><p><strong>Conclusion:</strong></p><p>No obvious gain in survival was observed with IRE as the first line treatment of LAPC and IRE was associated with severe complications. This study does not support percutaneous IRE in this setting.</p>
  •  
40.
  • Månsson, Christopher, Läkarexamen, 1977-, et al. (författare)
  • The Value of CA19-9 After Irreversible Electroporation for Pancreatic Cancer
  • 2019
  • Ingår i: Anticancer Research. - 0250-7005 .- 1791-7530. ; 39:11, s. 6193-6196
  • Tidskriftsartikel (refereegranskat)abstract
    • <p><strong>Background/Aim:</strong></p><p>Carbohydrate antigen 19-9 (CA19-9) is a tumor marker for pancreatic cancer. Irreversible electroporation (IRE) is an experimental treatment modality for pancreatic cancer. The aim of this study was to evaluate whether percutaneous IRE lowers the CA19-9 level in pancreatic cancer and whether this correlates with improved overall survival.</p><p><strong>Patients and Methods:</strong></p><p>Seventy-one patients with locally advanced pancreatic cancer or local recurrence after resection were treated. Patients with missing data, metastatic disease and normal serum CA19-9 before IRE were excluded. This left 35 cases for analysis.</p><p><strong>Results:</strong></p><p>The median CA19-9 did not decrease in the cohort after IRE treatment (282 U/ml before versus 315 U/ml after; p=0.80). The 25th percentile of patients with the best CA19-9 response had improved overall survival compared to the 25th percentile with the worst response (mean 13.1 versus 8.1 months, respectively; p=0.01).</p><p><strong>Conclusion:</strong></p><p>IRE did not lower the level of CA19-9 in pancreatic cancer cases. However, a response in CA19-9 was correlated with improved survival.</p>
  •  
Skapa referenser, mejla, bekava och länka
Åtkomst
fritt online (5)
Typ av publikation
tidskriftsartikel (124)
forskningsöversikt (12)
Typ av innehåll
refereegranskat (136)
övrigt vetenskapligt (1)
Författare/redaktör
Rubio, CA, (21)
Bergqvist, Michael, (10)
Andersson, Roland, (9)
Schmidt, PT, (8)
Nilsson, Jonas, (7)
Ansari, Daniel, (7)
visa fler...
Ekman, Simon (6)
Ramqvist, T, (5)
Dalianis, T, (5)
Bauden, Monika, (5)
Lindblom, A, (4)
Nilsson, Mats, (4)
Isacsson, Ulf, (4)
Henriksson, Roger, (4)
Andersson, Bengt-Åke ... (4)
Landerholm, Kalle, (3)
Bergqvist, M. (3)
Ekman, S, (3)
Nilsson, J, (3)
Lennernäs, Bo, 1963- ... (3)
Sundström, Magnus, (2)
Nilsson, S (2)
Nilsson, Sten, (2)
Janson, Christer, (2)
Berglund, Anders (2)
Adwall, Linda, (2)
Zhang, H (2)
Sharp, Lena (2)
Friesland, Signe (2)
Jaramillo, E (2)
Lindqvist, PG, (2)
Rubin, Kristofer, (2)
Nowinski, Daniel, (2)
Rutqvist, Lars Erik, (2)
Ursu, RG (2)
Haeggblom, L, (2)
Botling, Johan (2)
Sahlin, L, (2)
Bergstrom, S (2)
Marquez, M, (2)
Holmberg, AR (2)
Sandelin, Martin, (2)
Wågsäter, Dick, (2)
Palmqvist, Richard, (2)
Marklund, L, (2)
Falk Delgado, Albert ... (2)
Delgado, AF, (2)
Henic, Emir, (2)
Gerdin, Bengt, (2)
Lofgren, Sture, (2)
visa färre...
Lärosäte
Karolinska Institutet (52)
Uppsala universitet (23)
Lunds universitet (22)
Umeå universitet (12)
Linköpings universitet (7)
Göteborgs universitet (6)
visa fler...
Stockholms universitet (6)
Örebro universitet (4)
Högskolan i Jönköping (4)
Högskolan Kristianstad (1)
Kungliga Tekniska Högskolan (1)
visa färre...
Språk
Engelska (136)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (84)
Naturvetenskap (5)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy